A new form of inhaled insulin help people with diabetes and pose fewer risks than Exubera‚ an earlier form of inhaled insulin no longer on the market.
Afrezza is currently awaiting approval from the U.S. Food and Drug Administration. It works faster, keeps blood sugar at levels closer to normal‚ and carries a lower risk of causing hypoglycemia than currently available‚ injectable insulin. Afrezza also has less risk of causing lung problems than Exubera. Using a new technology called Technosphere‚ Afrezza is inhaled as a dry powder that dissolves in the lungs‚ which then passes into the bloodstream and starts working quickly‚ peaking at 12 to 15 minutes after inhalation. This helps keep after-meal blood sugar levels lower and is less likely to cause a blood sugar crash later.
No comments:
Post a Comment